Dr. Anil Koul, prior to taking the charge of Director, CSIR-IMTech, was Senior Director & Head, Respiratory Infections Discovery group at global healthcare giant Johnson & Johnson. He has more than 16 years of experience in pharmaceutical drug discovery research and clinical development. He obtained his Ph.D. from Max-Planck Institute for Biochemistry in Munich, Germany and Delhi University, Delhi. As a part of continued education, in 2011, he attended a short residential program at Harvard Business School, USA on innovation, strategy and leadership.
Dr. Anil Koul has been a key scientist in discovery and clinical development of SIRTUROTM (generically called Bedaquiline)- the first tuberculosis drug to be granted approved by United State FDA and EU in last 40 years. In 2013, he was awarded "Johnson Medal", the highest R&D prize by Johnson and Johnson for contributions to discovery and development of SIRTUROTM.Recently, he was invited to European Parliament to present to members of Europe-India Chamber of Commerce *EICC) on SIRTURO and global public health. Earlier, he was also awarded 'The Philip B. Hofmann Prize ' for his discovery of SIRTUROs mode of action and he has also been conferred with "Swiss-TB prize" by Switzerland's Society of Pneumologyfor outstanding scientific research in the year 2005.
Dr. Koul is a well-known and respected expert in Infectious diseases with >35 peer reviewed publications in leading journals like Nature and Science, > 40 presentations at International congress and more than 30 patents to this credit. He and his research team at Janssen have also discovered several new drugs (currently in clinical development) for diseases ranging from viral bronchiolitis/infections, novel antibiotics to animal health. Prior to Janssen,he worked in Germany in a biotech company on the development of kinase inhibitors for oncology and other diseases.
Dr. Koul is a visiting professor at Faculty of Sciences at Free University of Amsterdam, Netherlands. He has featured in Voice of America's scientific radio news analysis on challenges in drug development for neglected diseases.
- Recently appointed by Government of India's Ministry of Science and Technology and Prime Minister's Office as Head/Director of Institute of Microbial Technology (IMTECH), a National laboratory of CSIR. IMTECH's focusis on microbial research & technology development (www.imtech.res.in).
- 16 years of experience in pharmaceutical drug research in industrywithin infectious diseases/oncology. Till recently was senior director in drug discovery research at Johnson and Johnson pharmaceuticals.
- Key scientist involved in discovery and clinical development of SIRTURO (bedaquiline) – first drug to be approved in last 45 years for treatment of drug-resistant tuberculosis (www.sirturo.com).
- SIRTURO conditionally approved in several countries like US (2012) and EU (2014). In 2016, India's heath minister introduced the drug to MDR-TB patients (media link on page 5).
- In 2017, awarded 'Ranbaxy Pharmaceutical Research Award' for discovery of SIRTURO. Conferred in 2013 with 'Johnson Medal',the highest R&D prize at J&J for contributions to SIRTURO discovery. 'SwissTB prize' by Switzerland's Society of Pneumology in 2005.
- Published in leading scientific journals like Nature/Science etc. Holds several international patents and been invited speaker at international forums, including European Parliamentary forum.
- Interviewed by United States broadcasting service (Voice of America) in 2012 and NDTV in 2016 around SIRTURO (link on page 5). Recently had an honor to meet the Honorable Prime Minister, Shri Narendra Modi, during his visit to Brussels on 24th March, 2016.
- Visiting lecturer at Free University of Amsterdam, Amsterdam, Netherlands.
HONORS AND AWARDS
- 2017 Ranbaxy Pharmaceutical research award (Sun Pharma) for discovery of SIRTUROTM. www.sunpharma.com/responsibility/csr/ranbaxy-science-foundation
- 2013 Johnson Medal - highest prize in Johnson&Johnson for R&DofSIRTUROTM.
- 2008 "The Philip B.Hoffman" prize by TibotecNVfor discovering mechanism of action of SIRTUROTM.
- 2007 Public-private partnership project (Belgian government) as principal investigator (4 million Euros for identification of newer antibiotic drugs).(www.iwt.be)
- 2005 SwissTBprize by the Swiss Society of Pneumology (Switzerland). (www.swisstb.org).
- 1998 DAAD Research Fellowship from German Academic Exchange Service, Germany (www.daad.de).
- 1996 Junior Research Fellowship Government of India (http://www.csirhrdg.res.in).
- 1993 Student Fellowship from University of Delhi for PG course studies.